Phase 3a data from largest trial with liraglutide 3 mg demonstrated significantly greater weight loss versus placebo for adults with obesity
Bagsværd, Denmark, 16 May, 2014 – Results from the SCALE™ Obesity and Pre-diabetes phase 3a trial will be presented on 16 May, 2014 for the first time at the 23rd Annual Congress of the American Association of Clinical Endocrinologists (AACE). Data showed that after 56 weeks of treatment, liraglutide 3 mg, in combination with diet …